Related Compounds
Non-peptide or next-generation compounds frequently discussed alongside peptides including GLP-1 agonists, dual/triple agonists, and metabolic agents.
10 peptides in this category
5-Amino-1MQ
5-Amino-1MQ is a small-molecule methylquinolinium derivative that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that ...
Preclinical only (cell culture and mouse models). Growing clinical interest. NoRetatrutide
Retatrutide is an investigational first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it has demo...
Phase III trials ongoing (7 additional Phase III readouts expected in 2026). NotSurvodutide
Survodutide (BI 456906) is an investigational dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed by Boehringer Ingelheim. Unlike ...
Phase II trials completed for obesity and NASH (2023-2024). Phase III trials iniAmycretin
Amycretin is a novel, unimolecular long-acting dual agonist of both the GLP-1 and amylin receptors, developed by Novo Nordisk as a next-generation obesity and t...
Research ongoingOrforglipron
Orforglipron (brand name Foundayo, formerly LY3502970) is a first-in-class oral, non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly (orig...
Research ongoingMariTide (maridebart cafraglutide)
MariTide (maridebart cafraglutide, formerly AMG 133) is a novel bispecific antibody-peptide conjugate developed by Amgen, engineered to simultaneously antagoniz...
Research ongoingMazdutide
Mazdutide (IBI362, marketed as Xinermei in China) is the world's first approved dual glucagon (GCG)/GLP-1 receptor agonist, developed by Innovent Biologics unde...
Research ongoingCagriSema
CagriSema is an investigational fixed-dose combination of two distinct obesity medications in a single once-weekly subcutaneous injection: cagrilintide 2.4 mg (...
Research ongoingBLMP6 (Fibulin-4 Targeting Breast Cancer Peptide)
BLMP6 is a synthetic short peptide that binds the extracellular matrix protein fibulin-4 (FBLN4). It was identified by the Kolonin lab at McGovern Medical Schoo...
Preclinical. Efficacy demonstrated in mouse xenograft models of triple-negativeDA-1726
DA-1726 is an investigational oxyntomodulin-analogue peptide developed by MetaVia Inc. (Nasdaq: MTVA) as a once-weekly subcutaneous dual agonist at the glucagon...
Phase 1 active. Phase 1 Part 3a/3b titration studies ongoing as of May 2026; lon